Loading…
← CockpitCompetitor Analysis › 4151.T Kyowa Kirin Co LtdOpen in the cockpit ↗

Kyowa Kirin Co Ltd4151.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

Pharmaceutical company developing specialty biopharmaceuticals for nephrology, oncology and rare diseases.

≈ A specialty biopharma like a smaller AlexionMomentum strong 75
Mkt cap
$8.43B
US dollars, full cap
Free float
44%
of shares outstanding
$/day
$27.1M
20-day average traded
Fwd P/E
16.4×
forward earnings
ROIC−WACC
+6.5 pp
WACC 6.5%
Hurdle
-14 pp
Req g minus delivered
Next earnings
84 days
10 Feb 2027
Close · JPY¥2,552
1D-1.1%
1W+2.1%
1M+9.6%
3M-1.1%
6M+9.2%
YTD+2.4%
1Y+9.8%
ATR %2.7%
52w lowhigh11.1% off high

What Kyowa Kirin does

Pharmaceutical company developing specialty biopharmaceuticals for nephrology, oncology and rare diseases.

Earns from drugs it sells itself in Japan, notably in kidney disease, and from specialty medicines sold abroad such as Crysvita, a rare bone-disease antibody shared with Ultragenyx. Milestone and royalty payments from partners add to this. Kirin Holdings, the beverage group, holds the majority.

In one line: A specialty biopharma like a smaller Alexion.

Products and services

  • Nephrology drugs
  • Oncology drugs
  • Rare disease therapies

Customers

  • Hospitals/specialists (nephrology, oncology)

Where it sits in the supply chain

  • Pharmaceuticals
  • Biopharmaceutical drug development
  • Nephrology, oncology, rare disease…

What could go right

  • Specialty drug launches/global expansion

What could go wrong

  • Patent expiry/generic competition
  • Clinical trial failure risk

Moat: narrow (IP / patents, regulatory licence). Patent-protected specialty biologics in niche therapeutic areas with high regulatory barriers.

Headquarters: Tokyo, Japan · Founded: 1949 · Employees: 5,161

Named competitors

Kyowa Kirin at a glance

Size Kyowa Kirin (4151.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $8.43B, the 163rd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,552 on 18 Nov 2026.

Performance Over six months the shares gained 9.2%, against +16.7% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 10.4% over the last twelve months (peer median +16.2%); the operating margin is 24.3% (peer median 14.1%).

Valuation It trades at 16.4× forward earnings against a peer median of 20.8× (6th cheapest of 14).

Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.5 points above its cost of capital (6.5% WACC).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011012021 May 202621 Aug 202618 Nov 2026Peer median 1164151.T 112
Six months, rebased to 100: Kyowa Kirin against the median of its 20 peers (local-currency closes).

Kyowa Kirin financials

Reported figures in JPY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥532B¥497B¥496B¥442B¥398B
Revenue growth—0%+12%+11%—
Gross profit¥389B¥356B¥351B¥321B¥301B
EBITDA¥160B¥128B¥117B¥117B¥101B
Net income¥86.1B¥67.0B¥59.9B¥81.2B¥53.6B
Free cash flow¥73.7B¥58.9B¥41.8B¥98.3B¥33.1B
Capital expenditure¥77.2B¥83.5B¥105B¥32.9B¥28.7B
Total debt¥19.5B¥26.1B¥21.7B¥24.2B¥23.3B

Quarterly statements and history in the cockpit →

Kyowa Kirin competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-20%0%+20%PRAXPTGX2607RYTMGLENMARKALK-BALKSHLUN-A2196MDGLAMRXGRFKNSACORTSYRE3759002821CYTKIBRX4151.T6-month return →1-month return →
Up and to the right = strong over both horizons. Kyowa Kirin is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×500×1,000×1,500×PTGX2607GLENMARKMDGLKNSACORT37594151.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Kyowa Kirin is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%PTGX2607GLENMARKALK-BALKSHLUN-A2196AMRXGRFKNSACORT4151.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Kyowa Kirin is the large dot.

Kyowa Kirin competitors and peer comparison

Head to head with its named competitors (4151.T vs 4519.T vs AZN.L vs 4503.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Kyowa Kirin 4151.T$8.43B+9%+10%24%16.4×-4.7%
Chugai Pharmaceutical 4519.T$75.2B-8%+17%50%23.7×5.0%
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%
Astellas Pharma 4503.T$31.4B+17%+19%23%12.9×-9.0%
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%51.0×3.7%
Daiichi Sankyo 4568.T$31.4B+8%+17%13%18.4×7.6%
Eisai 4523.T$9.36B+11%+11%6%26.6×10.7%

How Kyowa Kirin compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Kyowa Kirin against its 20 peers (data as of 18 Nov 2026)
Measure4151.TPeer medianRank in peer set
1-month return+9.6%+2.2%9th highest of 21
6-month return+9.2%+16.7%9th lowest of 21
Distance from 52-week high-11.1%-13.6%10th highest of 21
Revenue growth (TTM)+10.4%+16.2%9th lowest of 20
Operating margin24.3%14.1%4th highest of 19
Forward P/E16.4×20.8×6th cheapest of 14
Growth the price implies (Req g, 7 yrs)-4.7%13.8%4th least demanding of 13
Growth delivered (Del g)+9.3%+9.0%7th highest of 13
Hurdle (Req g minus delivered)-14.0 pp+3.7 pp4th least demanding of 13
ROIC minus cost of capital+6.5 pp+1.4 pp6th highest of 17
EV / EBITDA7.0×22.6×cheapest of 12
Net debt / EBITDA-1.4×0.0×4th least indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%16.4×-4.7%+9.3%
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%1,532.5×17.5%+10.0%
Shanghai Pharmaceuticals 2607.HKHong Kong$8.25B-7%+9%3%6.3×-9.7%+7.4%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%n/an/an/a
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%33.1×27.3%+9.4%
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%34.8×7.3%+12.6%
Alkermes Public ALKSUnited States$7.87B+27%+15%5%n/a32.5%+7.3%
H. Lundbeck A/S HLUN-A.CODenmark$9.16B+69%+9%26%n/a-6.6%+6.6%
Shanghai Fosun Pharmaceutical (Group) 2196.HKHong Kong$7.74B-15%+10%6%9.0×19.9%+5.8%
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%81.5×n/an/a
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%19.2×17.2%+8.7%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
Spyre Therapeutics SYREUnited States$9.64B+41%n/an/an/an/an/a
Pharmaron Beijing 3759.HKHong Kong$9.65B+48%+24%14%20.8×n/an/a
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Asymchem Laboratories (Tianjin) 002821.SZChina$7.27B+20%+18%17%37.4×n/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a

Questions

Who are Kyowa Kirin's main competitors?
Named competitors: Chugai Pharmaceutical (4519.T), Alexion (AstraZeneca) (AZN.L), Astellas Pharma (4503.T), Takeda Pharmaceutical (4502.T), Daiichi Sankyo (4568.T), Eisai (4523.T). The cockpit's measured peer set (industry) also includes Praxis Precision Medicines (PRAX), Protagonist Therapeutics (PTGX), Shanghai Pharmaceuticals (2607.HK), Rhythm Pharmaceuticals (RYTM), Glenmark Pharmaceuticals (GLENMARK.NS), ALK-abello A/S (ALK-B.CO).
Is Kyowa Kirin expensive compared with its peers?
On forward p/e it trades at 16.4× against a peer median of 20.8×, 6th cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has Kyowa Kirin stock performed?
Over six months to 18 Nov 2026 the shares returned +9.2% against +16.7% for the median peer; over one year +9.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.